DMD gene therapy (Scriptr/CANbridge Pharmaceuticals)

N/A

Report date: 2025/01/26 19:12:47

Base Information

Drug NameDMD gene therapy (Scriptr/CANbridge Pharmaceuticals)
Drug Alias NameDMD gene therapy (Scriptr/CANbridge Pharmaceuticals)
ClassificationBiologics
Mechanisms of ActionDystrophin expression stimulants
TargetsDystrophin
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesScriptr Global Inc
China Registration ClassN/A

Develop Information

Active CompaniesScriptr Global IncCanbridge Life Sciences Ltd
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A